Search Results
Your search for ,SEE matches 4660 pages
Showing 2751 - 2800At the Forefront of Cancer Genetics, Bert Vogelstein, MD, Calls for Focus on Early Detection and Prevention
Bert Vogelstein, MD, was born on June 2, 1949, at The Johns Hopkins Hospital in Baltimore, Maryland, the same renowned institution where he would later make his mark in the field of cancer genetics. As a young teen, he was an enthusiast and independent consumer of books, one of which helped shape...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Pioneer in Geriatric Oncology, Hyman Muss, MD, Continues to Improve Care for Older Patients
Hyman Muss, MD, a pioneer in geriatric oncology, considers himself “a real Brooklyn boy.” His father was a dentist, and his uncle was a general practitioner. “They both practiced out of a small brownstone house in Brownsville-Crown Heights. It was sort of reminiscent of the famous movie The Last...
Clinical Researcher George P. Canellos, MD, Closely Involved With Two of the Most Influential Treatments in Cancer Care
George P. Canellos, MD, President of ASCO from 1993 to 1994, was born in Boston on November 1, 1934. “I came from a business family and never wanted to do business at all. As long back as I can remember, I always found medicine attractive—not only because you could help people, but you could also...
Nobel Laureate David Baltimore, PhD, Plays Integral Role in Linking Cell Biology and Cancer Genetics
David Baltimore, PhD, whose work profoundly influenced international science, was born on March 7, 1938, in Queens, New York, to Gertrude and Richard Baltimore. While he was in second grade, the family moved to Great Neck, New York, a middle-class suburb with top-notch public schools. “My father...
Renowned Hematologist Mojtaba Akhtari, MD, Reflects on a New Era in Treating Blood Cancers
The nationally recognized hematologist-oncologist Mojtaba Akhtari, MD, was born and reared in Tehran, Iran. “In my early years, I had a couple of cousins who were medical students. When I visited them in their homes, I was fascinated with the images in their medical text books. I would flip the...
Precision Medicine and My Own Activism Are Keeping Me Alive
In 2009, I was living my dream. My work as a business development manager for a technology company was thriving; I had a satisfying social life; I was active in sports, especially hiking and biking; and I was involved in social justice causes as a volunteer at San Quentin State Prison, helping...
Former Vice President Joe Biden and Congressman Kevin Yoder Pledge Continued Support to Conquer Cancer
In a nearly hour-long address to more than 4,500 attendees at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) on April 3, former Vice President Joe Biden lambasted President Trump’s proposed $5.8 billion budget cut to the National Institutes of Health (NIH) and...
Tackling the Obesity and Cancer Epidemic
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...
Unique Challenges Facing Young Women With Breast Cancer
According to the American Cancer Society, over 252,700 new cases of invasive breast cancer will be diagnosed in 2017, and about 40,610 women will die of their disease. Between 7% and 10% of those new cases will be diagnosed in women younger than age 40, accounting for more than 40% of all cancer...
What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?
As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...
Setting His Presidential Course on Making Precision Medicine a Reality for More Patients
Ensuring that all patients with cancer have access to the potential benefits of precision medicine regardless of where they are treated has been a primary goal of Bruce E. Johnson, MD, FASCO, since the concept was first introduced following completion of the Human Genome Project in 2003. Dr....
ASCO and Other Oncology, Medical Societies Speak Out Against White House’s Proposed Budget Cuts
On May 23, President Trump presented the White House’s fiscal year 2018 budget request, which proposes a $7.18 billion cut to the National Institutes of Health (NIH)—a budget decrease of 21%. In addition, it cuts the Center for Disease Control and Prevention’s chronic disease...
Hydroxychloroquine Boosts Antitumor Activity of Neoadjuvant Chemotherapy for Pancreatic Cancer
Adding hydroxychloroquine, an inhibitor of autophagy, to neoadjuvant chemotherapy for pancreatic cancer increases its efficacy and alters the tumor’s molecular profile in a way that may render the tumor more susceptible to immune checkpoint inhibitors, according to interim data from a phase II...
Complications From Thyroid Cancer Surgery More Common Than Once Thought
As thyroid cancer rates rise, more patients are having surgery to remove all or part of their thyroid. A new study by Papaleontiou et al in The Journal of Clinical Endocrinology & Metabolism suggests complications from these procedures are more common than previously believed. Overall, 6.5% of ...
Two Faculty Members From Johns Hopkins Elected to National Academy of Sciences
Johns Hopkins University faculty members Stephen B. Baylin, MD, and Robert F. Siliciano, MD, PhD, have been elected to the National Academy of Sciences in recognition of their “distinguished and continuing achievements in original research.” They are among 84 new members and 21 foreign associates ...
New Immunotherapy Combinations Gain Ground in Advanced Melanoma, but Results Preliminary
Attention is focused among the cancer community on identifying the optimal immunotherapy combinations, with more than 800 ongoing trials of combination therapy. Two studies presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) reported promising preliminary...
Expert Point of View: David L. Porter, MD & Jonathan S. Serody, MD
In a separate interview with The ASCO Post, David L. Porter, MD, Director of Blood and Marrow Transplantation and the Jodi Fisher Horowitz Professor in Leukemia Care Excellence at the University of Pennsylvania, Philadelphia, said: “It is encouraging that many patients with acute lymphoblastic...
Expert Point of View: Aditya Bardia, MD, MPH
Commenting on the phase I study of atezolizumab (Tecentriq) presented at the 2017 American Association for Cancer Research Annual Meeting, Aditya Bardia, MD, MPH, Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, said: “It is very encouraging to...
Atezolizumab Improves Overall Survival in Small Subset of Patients With Triple‑Negative Breast Cancer
Triple-negative breast cancer is an aggressive disease with no approved targeted therapy, and it remains challenging to treat. Early data from a phase I study suggest that the PD-L1 inhibitor atezolizumab (Tecentriq) can extend the lives of a subset of women who respond to this checkpoint...
Expert Point of View: Judy C. Boughey, MD
“Inflammatory breast cancer represents the aggressive end of the spectrum of breast cancer at presentation. It is encouraging It to see the high 5-year breast cancer–specific survival rates reported in this cohort of 114 women,” said Judy C. Boughey, MD, a breast surgeon at the Mayo Clinic,...
Triple‑Modality Therapy Achieves Good Control in Inflammatory Breast Cancer
Contemporary triple-modality therapy achieves excellent locoregional tumor control of inflammatory breast cancer, with only 4 locoregional recurrences out of 114 patients treated at The University of Texas MD Anderson Cancer Center, Houston. The investigators described their approach at the...
Expert Point of View: Denise A. Galloway, PhD
Denise A. Galloway, PhD, Associate Director, Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, whose research focus is human papillomavirus (HPV), told The ASCO Post that these findings provide new data for the field. “I can’t think of a large study of oral HPV infection in...
Prognostic Model May Prove Useful After Nephrectomy
A prognostic model proved able to accurately predict long-term outcomes for patients with stage I to III renal cell carcinoma, the developers of the instrument reported at the 2017 National Comprehensive Cancer Network Annual Conference.1 The model was derived from molecular tissue analysis and...
New Partnership Seeks to Raise Skin Cancer Awareness
The Skin Cancer Foundation recently announced a partnership with Amazon. The relationship is designed to demonstrate a shared commitment to raising awareness of the world’s most common cancer, now occurring at epidemic levels. Throughout 2017, The Skin Cancer Foundation and Amazon will work...
ASCO CEO Reflects on His First Year in Office and What Is Ahead
June 27, 2017, marks the 1-year anniversary since Clifford A. Hudis, MD, FACP, FASCO, began his tenure as Chief Executive Officer of ASCO. With the launch of the national Cancer Moonshot and the changes in the White House and Congress, it has been a year of tremendous activity drawing on all of...
Expect Questions From Patients Who ‘Do Everything Right’ but Still Develop Cancer
A study reported in Science found that more than two-thirds of human cancers are caused by random mutations made during DNA replication.1 “The main message we would like to convey is that even for many patients who follow all of the guidelines from the advisory bodies—they don’t smoke, exercise...
My Year of Living Wonderfully: 12 Months as ASCO President
EACH YEAR, the ASCO President chooses a theme for his or her term, which is not a trivial pursuit. Trying to think up something novel and catchy, yet not schmaltzy, is quite a challenge. However, in my year as Chair of the Scientific Program Committee for the 2010 ASCO Annual Meeting, then during...
‘It Is What It Is’
Mark looked at me shyly through his oversized Elvis Costello–style glasses. Was he feeling embarrassed by his own reply or just waiting for my reaction? He was sitting between his mom and dad, wearing a t-shirt with a huge Minion print. His braces showed when he smiled, something he does often in...
AUA 2017: Studies Highlight Shifts in Prostate Cancer Screening and Management
Active surveillance in men under 60, use of telemedicine in the management of prostate cancer, and physicians' personal prostate cancer screening preferences were all highlighted at the 2017 Annual Scientific Meeting of the American Urological Association (AUA). Active Surveillance for Low-Risk...
ASCO 2017: Gefitinib Treatment Can Delay Recurrence of Intermediate-Stage Lung Cancer
The targeted therapy gefitinib (Iressa) appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II to IIIA non–small cell lung cancer ...
ASCO 2017: Increase in Early-Stage Cancer Diagnoses After Implementation of the Affordable Care Act
An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Considering the thousands of people diagnosed with these cancers annually, a 1% increase in...
A New Book Deals With an Age-Old Crisis: Cancer Patients and Mortality
The field of psycho-oncology began to take hold in the mid-1970s, when the “C” word was beginning to lose its long-held stigmatization, and patients with cancer could finally begin to openly reveal their diagnosis and express their feelings about their life-threatening disease. Despite that social ...
Social Media: A Knowledge-Sharing Tool in Oncology
Social media is a uniquely positioned platform that can spread specific knowledge to a larger audience. Unlike traditional media, it allows anyone to join the conversation, and according to the Pew Research Center, it is here to stay, with 79% of online American adults using Facebook and 24% using...
SWOG Launches First Prospective Registration Trial With Atezolizumab in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
The standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer is radical cystectomy. Novel therapies that allow patients to preserve their bladder are urgently needed. SWOG (formerly the Southwest Oncology Group), a member of...
Karmanos Cancer Institute Now Offers Image-Fusion Technology to Detect Prostate Cancer
The Barbara Ann Karmanos Cancer Institute is using a sophisticated new way to diagnose and treat prostate cancer more effectively. Urology specialists at Karmanos have begun using the UroNav Fusion Biopsy System, which fuses three-dimensional MRI (magnetic resonance imaging) images of the prostate...
ELCC 2017: Osimertinib Improves Symptoms in Advanced Lung Cancer
Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented by Lee et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 85O). “With my...
CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...
CDK4/6 Inhibitors: Their Role in Breast Cancer
The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...
Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...
ELCC 2017: Men May Need More Frequent Lung Cancer Screening Than Women
Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task Force recommends annual screening for lung cancer with low-dose computed tomography (CT) in adults...
Noninvasive Imaging Test May Accurately Rule Out Kidney Cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT (single-photon emission computed tomography plus computed tomography) to conventional CT or magnetic resonance imaging...
Higher Rates of Bone Metastases and Increased Risk of Death in Follicular and Medullary Thyroid Cancer
In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death....
Pigmented Vascular Tumor
Nevus Vasculaire Albumen Print, Paris, 1869 Published in 1869, Revue Photographique des Hôpitaux de Paris was the world’s first medical journal to contain real photographs. In the seven issues produced between 1869 and 1875, 245 images were used. Dr. A. de Montméja, a Parisian ophthalmologist and...
Some Melanoma Survivors Continue to Seek Sun Exposure, Risking Second, Potentially More Serious Melanoma
Long-term survivors of melanoma are more likely than those who have not been diagnosed with the disease to use sunscreen, protective clothing, and other means to limit exposure to the sun, according to a survey of melanoma survivors and controls about ultraviolet radiation exposure and protective...
Fear Has Become a Big Part of My Survivorship
Just 32 when I first felt a lump in the top of my left breast, I never expected it to be cancer or my life would irrevocably change in that instant. With no history of breast cancer in my family, I initially shook off any thoughts that I could have a serious disease and instead consoled myself...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
Combination of Atezolizumab and Bevacizumab in PD-L1–Positive Patients With Metastatic Kidney Cancer
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) appears to be promising in the first-line treatment of patients with metastatic renal cell carcinoma, according to results of a phase II trial presented at the 2017 Genitourinary Cancers Symposium.1 Despite the failure of the...
Institute for Clinical Immuno-Oncology White Paper Highlights Challenges, Progress, and Priorities in Immunotherapy
Momentum around immunotherapies for cancer continues to build, but the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care. As these therapies are increasingly integrated into practice, all stakeholders—providers, patients,...
Two Studies Show Potential of Venetoclax as Single Agent and in Combination for Myeloma
Early-phase studies suggest that venetoclax (Venclexta) holds promise as a treatment for myeloma. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, investigators reported strong activity in heavily pretreated patients, especially those with the t(11;14)...
